Should you buy Thermo Fisher Scientific stock now?
Yes, the technical signal for Thermo Fisher Scientific is currently BUY. Thermo Fisher Scientific trades at $574.29 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 18.998 with rising momentum (signal: 18.626); RSI is at 66.9 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $629.50 points to 9.6% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Thermo Fisher Scientific stock?
The average analyst price target for Thermo Fisher Scientific is $629.50. The current price is $574.29, which gives an upside of 9.6%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $566.55 and $692.45.
Is Thermo Fisher Scientific a dividend stock?
Yes, Thermo Fisher Scientific is a dividend stock with a dividend yield of 0.31%. The latest dividend was $0.47 per share. The latest ex-dividend date (traded without the dividend) was 6/15/2026. The payout ratio is 7.6%, which is considered sustainable. The next dividend payment is scheduled for 10/15/2026.
When does Thermo Fisher Scientific pay a dividend in 2026?
Thermo Fisher Scientific pays its next dividend on 10/15/2026. The latest dividend was $0.47 per share with an ex-dividend date of 6/15/2026. The dividend yield is 0.31%. The payout ratio of 7.6% points to a sustainable dividend with room to grow.
What is the risk of Thermo Fisher Scientific stock?
Thermo Fisher Scientific is rated as a stock with moderately low risk. the annual standard deviation is 30.5%, which classifies the stock as moderately low risk.
Is Thermo Fisher Scientific overvalued?
Thermo Fisher Scientific is considered fairly valued – the price is close to the analyst price target. Thermo Fisher Scientific has the following valuation ratios: a P/E ratio of 30.3 (highly valued), a P/S ratio of 4.5, a P/B ratio of 4.1. The stock trades close to the analyst price target and is considered fairly valued.
Is Thermo Fisher Scientific overbought?
No, Thermo Fisher Scientific is not overbought. RSI is at 66.9 (neutral zone). The technical indicators show: RSI is at 66.9 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 4.2% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Thermo Fisher Scientific earnings report?
Thermo Fisher Scientific reports its next earnings on October 21, 2026. The stock currently trades at $574.29. With a P/E ratio of 30.3, the market will be watching closely whether earnings meet expectations. The RSI is at 66.9, so the report can reinforce the current technical trend.
Is Thermo Fisher Scientific shorted?
Yes, Thermo Fisher Scientific is shorted with 1.4% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Thermo Fisher Scientific stock?
No, insiders are not buying Thermo Fisher Scientific shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 226,000 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 56,249,170 $ sold. Active sellers include Pettiti Gianluca, Shafer Michael D, CASPER MARC N and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Thermo Fisher Scientific a good stock?
Based on our total score, Thermo Fisher Scientific is rated as a mediocre stock with a total score of 59 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 40/100, Quality: 61/100, Momentum: 75/100. In addition: a dividend of 0.31%; technical signal: Strong Buy. Whether Thermo Fisher Scientific is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Thermo Fisher Scientific stock?
The outlook for Thermo Fisher Scientific based on current data: the average analyst price target is $629.50 (+9.6%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 10/21/2026, which can move the price; the P/E ratio is 30.3 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Thermo Fisher Scientific stock rising?
Thermo Fisher Scientific is rising right now. The technical indicators show: the price is 4.2% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Thermo Fisher Scientific go?
The average analyst price target for Thermo Fisher Scientific is $629.50, which corresponds to a potential gain of 9.6% from the current price of $574.29. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Thermo Fisher Scientific fall?
We lack enough history to give a specific floor for Thermo Fisher Scientific. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Thermo Fisher Scientific do?
Thermo Fisher Scientific laver udstyr og løsninger til forskning og sundhed. De tjener penge på at sælge alt fra avancerede instrumenter til helt almindelige laboratorieprodukter, som bruges til at udvikle medicin og vacciner. Tænk på Bioscience-udstyr og klinisk next-generati... The company belongs to the Sundhed sector, more specifically the Diagnostics & Research industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Thermo Fisher Scientific as an investment.
Did Thermo Fisher Scientific raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Thermo Fisher Scientific. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Thermo Fisher Scientific making money or losing money?
Yes, Thermo Fisher Scientific is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 15.0% — which is solid. The operating margin (profit before interest and taxes) is 18.8%. At a P/E ratio of 30.3, you currently pay 30.3 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Thermo Fisher Scientific go bankrupt?
The bankruptcy risk of Thermo Fisher Scientific is rated as low. Altman Z2 (a model for assessing financial distress) is 3.70 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 96% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Thermo Fisher Scientific have a lot of debt?
Thermo Fisher Scientific has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 96%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Thermo Fisher Scientific service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 5.2x, and net debt equals 3.3 years of earnings (EBITDA).
